Bringing high-quality diagnostics for COPD and asthma to north Wales As a pharmacist prescriber at a community diagnostic respiratory hub in South Denbighshire, North Wales, Kevin Parvin explains why the hub is needed and how it is benefiting patients.…
More than 20,000 inhalers returned since November 2023 through recycling pilot Exclusive: Since its launch in November 2023, 20,400 inhalers have been returned through the ‘Re-Hale’ scheme, which operates across 78 locations in East Kent.…
How we recycled over 20,000 inhalers so far in East Kent NHS Kent and Medway Integrated Care Board explains how an inhaler recycling scheme was set up as a collaborative working project with biopharmaceutical company Chiesi.…
Over-the-counter nasal sprays reduce symptom duration in at-risk patients, study results suggest Antibiotic use was also reduced in all intervention groups.…
Community pharmacies to be commissioned to provide RSV vaccination programme The programme was announced following advice from the Joint Committee on Vaccination and Immunisation.…
Joint guidance for asthma recommends replacing SABA with corticosteroid inhalers The draft guidance proposes the use of combined inhaled corticosteroid/formoterol inhalers over previously preferred short-acting beta agonists.…
Greener inhaler propellant is therapeutically equivalent to traditional alternatives, study results suggest Study authors reported overall bioequivalence between inhalers that use HFA-152a as a propellant and traditionally used devices with HFA-134a as a propellant.…
‘Unresolvable conflict’: are links to big tobacco changing inhaler prescribing? The takeover of inhaler company Vectura by tobacco firm Philip Morris International has stirred up debate and controversy, with experts raising questions around whether the NHS is doing enough to make the connection clear to prescribers and patients.…
NHS spends £430m on inhalers linked to Philip Morris since Vectura takeover Exclusive: An analysis by The Pharmaceutical Journal of prescribing data has raised questions from experts on whether more should be done to highlight the inhalers‘ links to the tobacco company.…
NICE terminates appraisal of medicine for the treatment of persistent cough Manufacturer Merck Sharpe & Dohme has decided not to supply the National Institute for Health and Care Excellence with evidence on use of gefapixant (Lyfnua).…
